Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Thromboembolism 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

Gemcitabine 115130-nm albumin-bound paclitaxel 66Albumin-Bound Paclitaxel 44Fluorouracil 37Magnetic Resonance Spectroscopy 35Irinotecan 35pembrolizumab 34Taxes 33Specimen Handling 33Leucovorin 33Oxaliplatin 31Biopsy 23Cyclophosphamide 21Nivolumab 18fludarabine 16Radiosurgery 16Cisplatin 16Drug Therapy 15Capecitabine 12folfirinox 11durvalumab 11Radiotherapy 11irinotecan sucrosofate 10Ipilimumab 10Cetuximab 10Carboplatin 10Blood Specimen Collection 10olaparib 9Standard of Care 9dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × PEGPH20 × 1 year × Clear all
NCT02921022 2025-11-26

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Memorial Sloan Kettering Cancer Center

Phase NA Active not recruiting
110 enrolled
Gastrointestinal

Pancreatic Neoplasms, Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡